Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277582 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)
A Phase 2 study of Long QT Syndrome (LQTS) 2, sponsored by Thryv Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT07277582 is a Phase 2 study of Long QT Syndrome (LQTS) 2 that is actively recruiting participants, run by Thryv Therapeutics. The registered enrollment target is 64 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT07277582, a Phase 2 study of Long QT Syndrome (LQTS) 2, is actively recruiting participants, sponsored by Thryv Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions this study aims to answer are: Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)? What side effects or medical problems occur when participants take THRV-1268? Which dose of THRV-1268 works best and is safest? Participants will: Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 tablets twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B) Have clinic visits and tests to monitor safety and changes in their heart rhythm May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2.
Conditions Studied
Interventions
- OTHER baseline lead-in
- DRUG THRV-1268
Study Locations (6)
Arizona
- Honor Health Research and Innovation Institute - Scottsdale
California
- University of California San Francisco - San Francisco
Illinois
- University of Illinois Chicago - Chicago
Massachusetts
- Heart Center Clinical Research Program | MGH - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Wilmington Health - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277582
The ClinicalTrials.gov registry entry for NCT07277582 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thryv Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long QT Syndrome (LQTS) 2 appearing as the primary indexed condition, and to 2 interventions - of which baseline lead-in is the first listed.
NCT07277582 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT07277582 about?
NCT07277582 is a clinical study titled "Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)". The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions ...
What is the current status of trial NCT07277582?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2026-03-31. Estimated completion is 2027-06-30.
What conditions does trial NCT07277582 study?
This clinical trial studies the following conditions: Long QT Syndrome (LQTS) 2.
What interventions are being tested in trial NCT07277582?
The interventions under investigation include: baseline lead-in (OTHER), THRV-1268 (DRUG).
Who is sponsoring clinical trial NCT07277582?
This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277582 being conducted?
This trial has 6 study locations across Arizona, California, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.